From the Document: "The Coronavirus Disease 2019 (COVID-19) pandemic has caused strain on many health care and medical facilities around the country, and some doctors and pharmacists have altered conventional practice to accommodate the needs of patients during this public health emergency. Changed practices include maintaining increased supplies of Schedule II controlled substances needed for intubation at hospitals and increasing the use of telemedicine as an alternative to in-person patient visits with a provider. Such changes require the Drug Enforcement Administration (DEA) to make exceptions to Controlled Substances Act (CSA) regulatory requirements. DEA has made these and other accommodations during the COVID-19 public health emergency. This Insight focuses on DEA's regulatory role and how related polices have changed in response to the COVID-19 pandemic. The Food and Drug Administration (FDA) also plays a significant role in regulating the nation's drug supply, but is only briefly mentioned here."
CRS Insight, IN11321
Congressional Research Service: https://crsreports.congress.gov/